Table 1.
Clinicopathological data of the patients in NHCT and NCHT groups.
| Overall (n = 64) |
NCHT (n = 32) |
NHT (n = 32) |
p | |
|---|---|---|---|---|
| Age | ||||
| Mean(SD) | 67.88 (5.44) | 66.97 (5.68) | 68.78 (5.12) | 0.144 (wilcox.test) |
| median[IQR] | 68.00 [64.00, 71.25] | 67.00 [63.00, 70.25] | 69.00 [66.00, 72.25] | |
| Initial PSA | ||||
| 0-10 ng/ml | 2 (3.12%) | 1 (3.12%) | 1 (3.12%) | 0.040 (fisher.test) |
| 10-20 ng/ml | 2 (3.12%) | 1 (3.12%) | 1 (3.12%) | |
| 20-100 ng/ml | 32 (50.00%) | 11 (34.38%) | 21 (65.62%) | |
| >100 ng/ml | 28 (43.75%) | 19 (59.38%) | 9 (28.12%) | |
| Preoperative PSA | ||||
| 0-10 ng/ml | 59 (92.19%) | 32 (100.00%) | 27 (84.38%) | 0.053 (fisher.test) |
| 10-20 ng/ml | 3 (4.69%) | 0 (0.00%) | 3 (9.38%) | |
| 20-100 ng/ml | 1 (1.56%) | 0 (0.00%) | 1 (3.12%) | |
| Missing | 1 (1.56%) | 0 (0.00%) | 1 (3.12%) | |
| Gleason score | ||||
| < 8 | 23 (35.94%) | 12 (37.50%) | 11 (34.38%) | 1.000 (fisher.test) |
| ≥ 8 | 41 (64.06%) | 20 (62.50%) | 21 (65.62%) | |
| T stage | ||||
| T2c | 3 (4.69%) | 1 (3.12%) | 2 (6.25%) | 0.210 (fisher.test) |
| T3a | 21 (32.81%) | 7 (21.88%) | 14 (43.75%) | |
| T3b | 21 (32.81%) | 13 (40.62%) | 8 (25.00%) | |
| T4 | 19 (29.69%) | 11 (34.38%) | 8 (25.00%) | |
| N stage | ||||
| N0 | 32 (50.00%) | 12 (37.50%) | 20 (62.50%) | 0.079 (fisher.test) |
| N1 | 32 (50.00%) | 20 (62.50%) | 12 (37.50%) | |
| Biochemical recurrence | ||||
| Yes | 37 (57.81%) | 17 (53.12%) | 20 (62.50%) | 0.613 (fisher.test) |
| No | 27 (42.19%) | 15 (46.88%) | 12 (37.50%) | |